UC Davis surgeons enroll the first patient in an acute spinal cord injury study

This compound was previously known as Cethrin. Dr Lisa McKerracher is Founder of BioAxone and inventor of Cethrin. It is being developed by Vertex Pharmaceuticals.

UC Davis Health System – Sacramento, California – Neurosurgeons at UC Davis Health System have enrolled the first patient in a study that will determine if a new investigational treatment can safely and effectively improve motor function following acute traumatic cervical spinal cord injury. The treatment, a compound known as VX-210 being developed by Vertex Pharmaceuticals, could potentially block a molecule that plays a major role in preventing nerve regeneration.

Neurosurgeon Kim Kee

Neurosurgeon Kim Kee is leading the investigational study


The first patient was treated by Ripul Panchal, assistant professor of neurological surgery. The study will eventually include about 150 patients at 35 sites in North America.

Participants must be between 14 and 75 years of age and scheduled to undergo a spinal decompression/stabilization surgery within 72 hours following the initial injury. They will be randomized into three groups: two will receive the compound at two different doses and another will receive a placebo to the site of their injuries during surgery. At least four follow-up evaluations within 12 months after the surgical procedure are required for all participants.

For additional information and enrollment criteria for the VX-210 study at UC Davis, contact Nancy Rudisill at 916-734-3660 or narudisill@ucdavis.edu or visit clinicaltrials.gov.

UC Davis Full Article LINK

This entry was posted in Spinal Research and tagged , , , . Bookmark the permalink.

2 Responses to UC Davis surgeons enroll the first patient in an acute spinal cord injury study

  1. Lisa Landrum says:

    Will they have to start over with a phase I trial for Cethrin since one was done at Bioaxone?

    Lisa Landrum

    Sent from my iPhone

    >

Comments are closed.